Celerion consults in the scientific and regulatory phases of biopharmaceutical product development.
Celerion's experts have worked in both regulatory agency and industry roles on a wide variety of products, including innovative therapeutic proteins, therapeutic vaccines, monoclonal antibodies, somatic cell therapies, tissue-engineered products and biological generics. Consulting strategies encompass the biopharmaceutical development process from discovery through preclinical and clinical studies to post-marketing functions. Our scientists are very engaged in the practical interpretation of the requirements for biosimilar drugs emerging in Europe.